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Abstract
Background: Fibrates have been reported to cause paradoxical decreases in HDL-C in certain patients.
Design and methods: This post-hoc analysis explored the frequency/magnitude of HDL-C reductions in a pooled
database of mixed dyslipidemic patients (LDL-C:3.4-5.7 mmol/L;TG:1.7-5.7 mmol/L) receiving placebo (PBO),
fenofibrate (FENO), ezetimibe plus FENO (EZE+FENO), or EZE/simvastatin plus FENO (EZE/SIMVA+FENO) for 12
weeks.
Results: PBO-treated patients had the highest incidence of HDL-C reductions from baseline (45%) compared with
patients taking FENO (14%), EZE+FENO (9%), or EZE/SIMVA+FENO (9%). Reductions <30% reflected natural
variability since the largest reduction in HDL-C approached 30% in the PBO group. Only 3 patients exhibited HDL-C
reductions ≥30% (i.e., 2 patients in the FENO group and 1 in the EZE+FENO group). There were no differences in
demographic/biochemical characteristics between patients with and without HDL-C reductions.
Conclusions: The incidence of paradoxical HDL-C reductions was low in mixed dyslipidemic patients receiving
FENO alone or combined with EZE or EZE/SIMVA.
Trial registrations: Clinicaltrials.gov: NCT00092560 and NCT00092573
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Background
Plasma concentrations of high-density lipoprotein cho-
lesterol (HDL-C) are inversely correlated with coronary
heart disease (CHD) risk, even after adjusting for lipid
and non-lipid risk factors [1]. This negative association
is maintained even at very low levels of low-density lipo-
protein cholesterol (LDL-C) [2]. As a consequence,
increasing HDL-C has emerged as an attractive tool for
preventing cardiovascular events. Moreover the presence
of atherogenic dyslipidemia, which is characterized by
low HDL-C and elevated fasting and postprandial trigly-
ceride (TG) levels, contributes strongly to CHD risk
even when LDL-C is well controlled [3,4]. The athero-
genic dyslipidemia phenotype is usually observed in
patients with mixed dyslipidemia, type 2 diabetes and/or
metabolic syndrome [5]. Beyond lifestyle approaches,
fibrates are one of the available strategies to treat
atherogenic dyslipidemia and to prevent CHD [5,6].
Fibrates are agonists of peroxisome proliferator-acti-
vated receptor-a (PPAR-a). By activation of PPRA-a,
fibrates impact multiple pathways of lipid metabolism
while also exerting pleiotropic effects through the regu-
lation of genes influencing vascular inflammation and
thrombogenesis [7]. Several large-scale trials of fibrate
therapy have been completed with conflicting results on
cardiovascular outcomes [8-11]. However, recent meta-
analyses have shown that fibrates can reduce the risk of
cardiovascular events predominantly through the pre-
vention of coronary events [12,13]. Moreover post-hoc
analyses of several of these fibrate trials and meta-ana-
lyses provided consistent evidence of a clinical benefit in
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[5,14].
Fibrates modulate the atherogenic lipid profile by con-
comitantly lowering TG levels (up to 50%) and raising
HDL-C levels (up to 10%-15%) [15]. These effects differ
among fibrates, and the long-term HDL-raising effect is
less (<5%) in people with type 2 diabetes [4,9]. In a
recent meta-analysis, the mean HDL-C increase
observed following fenofibrate (FENO) therapy was
10.2% [12]. Several recent reports have suggested that
fibrates, particularly FENO, may cause paradoxical
reductions in HDL-C levels in certain patient popula-
tions, such as patients with type 2 diabetes, elevated or
reduced pre-treatment HDL-C levels, and following con-
comitant use with statins and/or other medications (e.g.,
thiazolidinediones) [16,17]. However, there is wide varia-
bility in the documented literature regarding the fre-
quency and magnitude of paradoxical HDL-C
reductions seen in association with FENO treatment.
The absence of placebo-treated patients in these studies
precluded an assessment of whether these paradoxical
HDL-C reductions were in part due to the natural varia-
bility in HDL-C changes over time and/or differences in
measurement techniques between studies.
The purpose of this post-hoc analysis was to explore
the frequency and magnitude of paradoxical HDL-C
reductions during FENO therapy in a large pooled data-
base of mixed dyslipidemic patients receiving placebo,
FENO monotherapy, or FENO in combination with eze-
timibe (EZE) or EZE/simvastatin (SIMVA) treatments.
This pooled analysis offers several advantages over prior
studies, including the large number of FENO-treated
patients (n = 731) contributing to the analysis and the
presence of a placebo group, which served as a control
for the natural variability in HDL-C changes over time
in this population of mixed dyslipidemic patients. More-
over, this analysis gives the opportunity to obtain infor-
mation on this paradoxical effect when FENO is
combined with other lipid-lowering drugs.
Results
Of 854 patients in the pooled database with paired
HDL-C values at baseline and study end, a total of 139
( 1 6 % )p a t i e n t si na l lg r o u p sh a dr e d u c t i o n sf r o mb a s e -
line in HDL-C at study endpoint (Table 1). A similar
proportion of PBO-treated patients experienced HDL-C
increases and HDL-C decreases at study endpoint (i.e.,
52% vs. 45%, respectively). The overwhelming majority
of patients in the active treatment groups experienced
increases from baseline in HDL-C (i.e., 84% in FENO
group and 89% in each the EZE + FENO and EZE/
SIMVA + FENO groups). PBO-treated patients had the
highest incidence of HDL-C reductions from baseline
(45%) compared with patients taking active treatment
with FENO alone (14%), EZE + FENO (9%), or EZE/
SIMVA + FENO (9%). The incidence of paradoxical
HDL-C reductions was lowest in the EZE + FENO and
EZE/SIMVA + FENO groups. A small and similar pro-
portion of patients experienced no change from baseline
in HDL-C across the treatment groups. As a result,
patients who experienced increases or no changes from
baseline in HDL-C were pooled together within each
treatment group for the purpose of all categorical
analyses.
Distribution graphs for percent change from baseline
in HDL-C at study endpoint were examined for each of
the individual treatment groups (Figure 1). For the PBO
group, patients had increases ranging from >0% to 50%
and decreases from baseline ranging from >0% to
approximately 30% at study endpoint, with the majority
of the increases and decreases from baseline ranging
from 0% to approximately 20% (Figure 1A). In compari-
son, patients in the FENO, FENO + EZE, and FENO +
EZE/SIMVA groups had increases ranging from >0% to
90% and decreases from baseline ranging from >0% to
60% at study endpoint (Figure 1B-1D). Most patients
receiving FENO experienced increases in HDL-C ran-
ging from >0% to 40% irrespective of whether FENO
was administered alone or in combination with EZE or
EZE/SIMVA (Figure 1B-1D). The majority of patients in
the FENO, EZE+FENO, and EZE/SIMVA+FENO groups
experienced small reductions in HDL-C on the order of
0% to approximately 20% from baseline (Figure 1B-1D).
The baseline demographics and lipid characteristics
were generally similar for the cohorts of patients experi-
encing reductions and increases/no change in HDL-C at
study endpoint (Table 2). In general, patients with
HDL-C reductions at study end had slightly higher
HDL-C and Apo AI values and slightly lower non-HDL-
C and TG levels at baseline (Table 2).
The distributions in HDL-C values at baseline and study
endpoint were plotted for each of the individual treatment
groups (Figure 2). The distributions of HDL-C levels were
Table 1 Numbers (%) of patients with increases, no
change, or decreases from baseline in HDL-C at endpoint
presented by treatment group
HDL-C increase and no
change
Treatment Group HDL-C
increase
n (%)
No
change
n (%)
HDL-C
decrease
n (%)
PBO (n = 123) 64 (52.0) 4 (3.3) 55 (44.7)
FENO (n = 368) 309 (84.0) 8 (2.2) 51 (13.9)
EZE+FENO (n = 183) 163 (89.1) 3 (1.6) 17 (9.3)
EZE/SIMVA+FENO (n =
180)
161 (89.4) 3 (1.7) 16 (8.9)
EZE = ezetimibe; FENO = fenofibrate; PBO = placebo; SIMVA = simvastatin
Farnier et al. Lipids in Health and Disease 2011, 10:212
http://www.lipidworld.com/content/10/1/212
Page 2 of 9nearly identical at baseline and study endpoint for patients
receiving PBO (Figure 2A). In contrast, there was a shift to
the right (i.e., shift toward higher HDL-C levels) in the dis-
tribution of HDL-C values at endpoint relative to baseline
in patients receiving FENO, EZE+FENO, and EZE/SIMVA
+ FENO (Figure 2B-2D).
Modest reductions from baseline <30% were consid-
ered to reflect natural variability in the HDL-C measure-
ment since the largest observed reduction from baseline
in HDL-C approached 30% in the PBO group (Figure
1A). In general, the incidences of HDL-C reductions
<30% were similar across the PBO, FENO, EZE + FENO
and EZE/SIMVA + FENO groups (Table 3). Only three
patients exhibited reductions in HDL-C of ≥30% in
magnitude (i.e., 2 patients in the FENO group and 1
patient in the EZE + FENO group; Table 3). The actual
observed HDL-C reductions for these three patients
were 57%, 49%, and 30% (Table 4). Two of the three
patients had Apo AI reductions that were generally
commensurate with the observed HDL-C reductions
whereas one patient with an HDL-C reduction of 30%
had an Apo AI reduction of only 2.4%. None of these
patients were taking concomitant medications with a
known potential to modify HDL-C levels.
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Figure 1 Distribution in mean percent. Distribution in mean percent changes from baseline in HDL-C for patients in the placebo group (n =
123) (A); fenofibrate 160 mg group (n = 368) (B); ezetimibe 10 mg plus fenofibrate 160 mg group (n = 183) (C); and ezetimibe/simvastatin 10/
20 mg plus fenofibrate 160 mg group (n = 180) (D)
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This was a pooled post-hoc analysis of data from two
multicenter, international, randomized, double-blind,
placebo-controlled, parallel-group studies (Merck Proto-
col Numbers MK-0653A-036 and MK-0653-071; Clini-
cal registrations: NCT#00092560 and NCT#00092573).
Eligible patients included men and women 18 to 79
years of age with mixed hyperlipidemia and no CHD,
CHD-equivalent disease (except for type 2 diabetes), or
CHD risk score >20% as defined by the National Cho-
lesterol Education Program Adult Treatment Program
III (NCEP ATP III).
The studies were conducted in accordance with prin-
ciples of Good Clinical Practice, and the protocols and
procedures were approved by an Ethics Review Commit-
tee (ERC) or Institutional Review Board (IRB) for each
participating study site. Merck’s approach to the con-
duct of clinical trials is in accordance with the ethical
principles that have their origin in the Declaration of
Helsinki, and that are consistent with Good Clinical
Practice and the applicable regulatory requirement(s).
Prior to any study-related procedures, all planned proce-
dures and inherent risks were reviewed with each
patient and/or their representative, and all patients pro-
vided written informed consent to participate in the
study.
After a drug washout and a PBO run-in period with
dietary and life style counseling, patients were allowed
to enter the studies if their plasma lipid concentrations
met the following criteria for randomization: LDL-C 3.4
to 5.7 mmol/L and TG 1.7 (2.3 for EZE/SIMVA +
FENO study) to 5.7 mmol/L inclusive. Patients with
type 2 diabetes were limited to those with LDL-C 2.6 to
4.7 mmol/L, inclusive.
In the first study, qualifying patients were randomized
to one of the following daily treatments for 12 weeks:
PBO (n = 64); FENO 160 mg (n = 189); EZE 10 mg (n
= 187); or EZE 10 mg +FENO 160 mg (n = 185). In the
second study, qualifying patients were randomized to
one of the following daily treatments for 12 weeks: PBO
(n =6 0 ) ;F E N O1 6 0m g( n = 184); EZE/SIMVA, n =
184); EZE/SIMVA 10/20 mg + FENO 160 mg (n = 183)
For the purpose of this analysis, available data from
the PBO (n = 123) and FENO (n = 368) arms were
combined across studies, and data from the PBO,
FENO, EZE+FENO, and EZE/SIMVA+FENO arms were
included in the analysis.
All lipid and apolipoprotein (Apo) analyses for the two
studies were performed using the same validated assay
methods at the same central laboratory (either PPD
facilities, Medical Research Laboratory, Highland
Heights, Kentucky, USA or Zaventem, Belgium).
This analysis examined the frequency and magnitude
of HDL-C changes from baseline in each of the four
treatment groups. The numbers and percentages of
patients with HDL-C decrease, no change, and increase
Table 2 Demographics and baseline characteristics of patients with increases/no change or decreases from baseline in
HDL-C at endpoint
HDL-C increase and
no change
HDL-C decrease All patients
Demographic Parameters
Mean age ± SD, years (n) 54.6 ± 10.3 (715) 52.6 ± 10.8 (139) 54.3 ± 10.4 (854)
<65 years, n (%) 578 (80.8%) 122 (87.8%) 700 (82.0%)
≥65 years, n (%) 137 (19.2%) 17 (12.2%) 154 (18.0%)
Gender, n (%)
Female 340 (47.6%) 57 (47.6%) 397 (46.5%)
Male 375 (52.4%) 82 (59.0%) 457 (53.5%)
Race category, n (%)
Caucasian 561 (78.5%) 111 (79.9%) 672 (78.7%)
Non-Caucasian 154 (21.5%) 28 (20.1%) 182 (21.3%)
History of diabetes, n (%) 86 (12.0%) 20 (14.4%) 106 (12.4%)
Baseline Parameters, mmol/L (n)
Mean HDL ± SD 1.1 ± 0.2 (715) 1.2 ± 0.3 (139) 1.1 ± 0.2 (854)
Mean Apo AI ± SD (g/L) 1.5 ± 0.2 (706) 1.6 ± 0.4 (134) 1.5 ± 0.3 (840)
Mean LDL-C ± SD 4.2 ± 0.7 (715) 4.2 ± 0.7 (139) 4.2 ± 0.7 (854)
Mean Apo B ± SD (g/L) 1.7 ± 0.2 (706) 1.6 ± 0.3 (134) 1.6 ± 0.2 (840)
Mean Non-HDL-C ± SD 5.6 ± 0.8 (715) 5.4 ± 0.8 (139) 5.6 ± 0.8 (854)
Mean TC ± SD 6.7 ± 0.9 (715) 6.6 ± 0.8 (139) 6.7 ± 0.8 (854)
Median TG ± SD 2.9 ± 1.0 (715) 2.7 ± 1.1 (139) 2.9 ± 1.0 (854)
Apo = apolipoprotein; LDL-C = low-density lipoprotein cholesterol; HDL-C = high-density lipoprotein cholesterol; SD = standard deviation; TC = total cholesterol;
TG = triglycerides
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Page 4 of 9at the end of treatment versus baseline were tabulated
by treatment arms. The proportions of patients with no
change in HDL-C at study end were low and similar
across the treatment groups. As a result, the frequency
of HDL-C increases and frequency of no change from
baseline were summated together for the purpose of all
categorical analyses. The distributions of the percentage
change from baseline in HDL-C values at study end-
point as well as HDL-C values pre- and post-treatment
were displayed as histograms for each of the treatment
groups.
Descriptive statistics of the baseline characteristics and
plasma lipid profiles for patients with HDL reductions
versus those with HDL increases (or no change) were
summarized. The age, gender, body mass index (BMI),
concomitant medications, and baseline/endpoint HDL-
C, TG, and Apo AI values were evaluated for every
patient receiving active treatment (i.e., FENO, EZE +
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Figure 2 Distribution of HDL-C values. Distribution of HDL-C values (mmol/L) at baseline and study endpoint for patients in the placebo
group (n = 123) (A); fenofibrate 160 mg group (n = 368) (B); ezetimibe 10 mg plus fenofibrate 160 mg group (n = 183) (C); and ezetimibe/
simvastatin 10/20 mg plus fenofibrate 160 mg group (n = 180) (D)
Table 3 Proportions of patients (%) in each treatment
group with reductions from baseline in HDL-C < and
≥30% at endpoint
Treatment Group <30% ≥30%
PBO 55/55 (100) 0
FENO 49/51 (96) 2/51 (4)
EZE+FENO 16/17 (94) 1/17 (6)
EZE/SIMVA+FENO 16/16 (100) 0
EZE = ezetimibe; FENO = fenofibrate; PBO = placebo; SIMVA = simvastatin
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reductions ≥30%. The cut point of ≥30% was selected
since the maximum percentage change from baseline in
HDL-C values for individual patients observed in the
placebo group approached 30%.
Discussion
This post-hoc pooled analysis of two previously pub-
lished randomized, double-blind, placebo-controlled stu-
dies examined the incidence of paradoxical reductions
from baseline in HDL-C following treatment with
FENO (i.e., FENO administered alone or in combination
w i t hE Z Eo rE Z E / S I M V A )o rP B Of o r1 2w e e k si na
large population of patients (N = 854) with mixed dysli-
pidemia. The present analysis was undertaken to evalu-
ate whether paradoxical HDL-C reductions following
FENO treatment is a common or a rare occurrence.
Prior studies have examined this question and arrived at
very different conclusions. A retrospective analysis of
lipid data from 94 patients taking FENO (i.e.,
micronized FENO 200 mg or supra-micronized FENO
160 mg) for 8 to 12 weeks showed that reductions in
HDL-C occurred in almost half of the study population
(i.e., 46%)[18]. Nine patients (9.6%) in that study experi-
enced large magnitude HDL-C reductions of >50%. The
reductions in HDL-C appeared to occur more frequently
in patients with low pre-treatment HDL-C levels (<0.9
mmol/l). A subsequent retrospective analysis of lipid
data from 581 patients reported that the incidence of
paradoxical HDL-C reductions was a relatively uncom-
mon phenomenon occurring in only 15% of the study
population, with overall modest decreases from baseline
in HDL-C (<50%) [19].
Beyond these analysis, a number of cases have been
reported in the literature in which fibrates, particularly
FENO and ciprofibrate, have been associated with para-
doxical reductions in HDL-C levels[16,20,21]. These
paradoxical decreases seem more frequent when a
fibrate is combined with thiazolidinediones [17,22-26].
Other reports suggest a higher risk of paradoxical
Table 4 Detailed listing of concomitant medications and patient characteristics for the 3 patients with HDL-C
reductions ≤30% at study endpoint
HDL-C (mmol/L) Triglycerides
(mmol/L)
Apo AI (g/L)
Treatment Concomitant Therapy Age
(yr)
Sex BMI Baseline Endpoint
(% change)
Baseline Endpoint
(% change)
Baseline Endpoint
(% change)
Reduction between 30%-40%
Feno None 36 Male <30 1.04 0.73
(-30.00)
3.48 3.59
(3.25)
1.26 1.23
(-2.38)
Reduction between >40%-50%
EZE+Feno celecoxib 43 Female <30 0.85 0.44
(-48.48)
3.44 2.25
(-34.65)
1.18 0.53
(-55.1)
acetaminophen
clonazepam
chlorthalidone
propanolol HCl
Reduction over 50%
Feno acetaminophen acetylcysteine 52 Male <30 1.07 0.47
(-56.63)
1.94 3.27
(68.02)
1.47 0.54
(-63.3)
cetrimide+naphazoline nitrate
+phenylephrine hydrochloride
+prednisolone
fenspiride hydrochloride
bacitracin zinc + tixocortol pivalate
oxomemazine
ibuprofen
telithromycin
guaifenesin+oxomemazine+sodium
benzoate
allopurinol
niaouli oil+quinine benzoate+thiamine
HCl
losartan potassium
BMI = body mass index; EZE = ezetimibe; Feno = fenofibrate
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therapy [16,27] and for patients with diabetes [27]. It is
important to confirm or disprove a specific risk for dia-
betic patients treated with a statin since this statin treat-
ment is recommended for almost all patients with type
2 diabetes [28,29] and since a combination with FENO
seems particularly useful for patients with atherogenic
dyslipidemia [4,14].
In the current pooled analysis of mixed dyslipidemic
patients, the overall incidence of paradoxical HDL-C
reductions was approximately 11.5% (84/731) across the
pooled FENO (i.e., FENO, EZE + FENO and EZE/
SIMVA + FENO) treatment groups compared with
44.7% (55/123) in PBO-treated patients.
There were no ascertainable differences in the baseline
demographics between patients who experienced HDL-
C reductions and those who experienced increases/no
change from baseline. In general, patients with HDL-C
decreases had slightly higher HDL-C and Apo AI values
and slightly lower non-HDL-C and TG levels at base-
line. This finding suggests that a regression to the mean
phenomenon may be at least in part responsible for the
observed reductions in HDL-C seen with PBO and
FENO treatment in this study. The HDL-C levels in a
patient with high pre-treatment HDL-C values might be
expected to decrease due to a natural tendency to
regress to the population mean.
Modest reductions from baseline <30% were consid-
ered to reflect natural variability in the HDL-C measure-
ment [30] since the largest observed reduction from
baseline in HDL-C approached 30% in the PBO group.
The vast majority of FENO-treated patients (96%) had
HDL-C reductions from baseline <30% in magnitude.
Only three patients in the FENO-treated groups (2
patients taking FENO and 1 patients taking EZE+FENO)
had HDL-C reductions from baseline of 30% or more.
For the first patient, the decrease in HDL-C was not
associated with a reduction in the Apo AI level. This
finding also suggests that the observed reduction in
HDL-C for this patient was due to the variability in the
dosage of HDL-C[30]. For the two other patients, the
observed reductions in Apo AI (-55% and -63%) were
commensurate with the observed magnitude reduction
in HDL-C (-49% and -57%, respectively). There were no
notable differences in the demographic or baseline char-
acteristics of the three patients with HDL-C reductions
≥30% compared with other patients included in this
analysis. Furthermore, none of these patients were tak-
ing prescription and/or non-prescription medications
with a known propensity to modify HDL-C levels.
The mechanism of action(s) underlying the paradoxi-
cal decreases in HDL-C seen following fibrate treatment
remains unresolved. A pharmacogenetic association
between the Apo AI/C3/A4/A5 gene cluster and lipid
responses to fenofibrate has been described[31]. But the
reported results do not support a role for this gene clus-
ter in large magnitude HDL-C reductions. The corre-
sponding decrease in Apo AI seen with HDL-C
reductions in the current study suggests a role for Apo
AI metabolism. A prior study evaluated the metabolism
of Apo AI and Apo AII in a single patient with a para-
doxical reduction in HDL-C due to ciprofibrate[32].
This study found an increased production rate of Apo
AI and decreased residence time at baseline, and a
further decreased residence time during ciprofibrate
treatment while production rate remained increased. A
putative interaction with the peroxisome proliferator
response elements in the promoter for the Apo AI gene
cannot be excluded.
It is worth noting that treatment with FENO, EZE +
FENO, and EZE/SIMVA + FENO did produce expected
increases from baseline in HDL-C. Most patients treated
with FENO had increases from baseline in the 10% to
50% range, demonstrating the effectiveness of FENO
treatment in raising HDL-C levels. In contrast, relatively
few patients receiving PBO (i.e., 52%) had increases
from baseline in HDL-C versus 84%, 89%, and 89% of
the patients in the PBO, FENO, EZE + FENO and EZE/
SIMVA + FENO groups, respectively. The magnitudes
of the increases in HDL-C were considerably smaller in
the PBO-treated patients than FENO-treated patients.
Taken together, the results of our findings do not sub-
stantiate findings in a previous publication that reported
a high incidence (46%) of large magnitude reductions in
HDL-C (>50%) in patients receiving FENO treatment
[18]. In contrast, the results of this current large, pooled
analysis demonstrate that the incidence of HDL-C
reductions occurred less frequently in FENO-treated
patients than in PBO-treated patients (12% versus 45%,
respectively). Furthermore, the vast majority of HDL-C
reductions seen in FENO-treated patients were modest
in magnitude (<30%) and similar to those seen among
PBO-treated patients. Only two patients in the current
study had HDL-C reductions >50%, with concomitant
and similar decreases in Apo AI. These patients did not
have a diagnosis of diabetes and were receiving statin
treatment. In this analysis, there were no specific patient
characteristics predictive of the risk of HDL-C decrease.
In conclusion, the overall incidence of paradoxical
HDL-C reductions was low in this pooled analysis of
mixed dyslipidemic patients receiving FENO alone or
combined with EZE or EZE/SIMVA.
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